Mir Sohail Fazeli, MD, PhD
Mir Sohail Fazeli, MD, PhD

Mir Sohail Fazeli, MD, PhD

Founder & Chief Executive Officer

Dr. Mir Sohail Fazeli comes with over two decades of experience working within academia and industry as the principal investigator, project lead, and clinical research consultant. His research experience in evidence generation and synthesis covers a broad range of methodologies, including systematic and targeted literature reviews of clinical trials and observational studies, meta-analyses, network meta-analyses, and complex statistical modelling studies.

Drawing upon years of hands-on medical practice in emergency care and family medicine, alongside a robust background in academic and industry research, Mir stands as a dedicated consultant who consistently lends his expertise to pharmaceutical clients across a spectrum of essential functions. These encompass Clinical Development, Medical Affairs, Safety and Epidemiology, Health Economic and Outcomes Research, Research and Development, as well as Scientific Communications and Publications.

Mir earned his PhD from the University of British Columbia, where his research primarily delved into the autonomic nervous system. This academic journey yielded several publications, among which is a noteworthy chapter in the 2018 “Evidence-based Urology” (2nd edition) by Wiley-Blackwell. This chapter serves as a valuable resource for urologists, physicians, and residents alike.

Interests/hobbies: Nature, Reading, Chess, History and Philosophy

Mariana Machado, BMktRobyn Kendall, MSc, BSc

Michael del Aguila

Michael del Aguila comes to Evidinno with 25 years experience in consulting and work inside Life Sciences companies in support of market access and real world evidence generation.  This includes executive positions at Roche, Genentech, Bristol-Myers Squibb and Gilead. 

In BioPharma Michael led teams responsible for sponsored real world evidence and HEOR clinical and observational studies, as well as market access and pricing. His executive leadership in consulting services has included those same domains.

He is pleased to have the opportunity to lead Evidinno’s expansion in product offerings and customer base as we continue our growth trajectory. 

Interests/hobbies: Theater, live music, hiking and running

Jean Paul Collet

Jean-Paul is the Chief Scientific Officer at Evidinno. JP is a trained pediatrician with MSc in Health Economics and PhD in Epidemiology from McGill University. He’s been a Professor and Associate Head Research in the Department of Pediatrics at UBC since 2006. JP’s career in clinical research has been associated with receiving many competing grants (over $30 million), the supervision of over 50 students completing MSc, PhD or Postdoc, and numerous publications (200+) with many of them related to drug evaluation methodology, economic impact and outcomes research.

Interests/hobbies: Practicing Tai Chi and Hiking; Holistic approach for self-development; Philosophy

Masoud Pourrahmat

Masoud Pourrahmat acts as the Head of Operations at Evidinno. With a career spanning over a decade, he possesses extensive expertise in the field of HEOR. Masoud has demonstrated exceptional competence in overseeing and executing targeted or systematic literature reviews, meta-analyses, network meta-analyses, and surrogacy analyses of clinical outcomes. His contributions have encompassed diverse areas such as oncology, neurology, cardiology, endocrinology, immunology, and digital health, among others.

Interests/hobbies: Reading, history, cooking.

Mir Sohail Fazeli

Dr. Mir Sohail Fazeli is the President and Managing Director at Evidinno Outcomes Research Inc. He has over two decades of experience working within academia and industry acting as the principal investigator, project lead, and medical research consultant. His work in evidence synthesis covers a diverse range of methodologies, including systematic and targeted literature reviews of clinical trials and observational studies, meta-analyses, network meta-analyses, and complex statistical modelling studies.